Skip to content

Serotonin Levels in Atopic Dermatitis Patients

Serotonin Levels in Atopic Dermatitis Patients and Its Relation to Disease Severity

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03471819
Enrollment
50
Registered
2018-03-21
Start date
2018-04-01
Completion date
2019-04-30
Last updated
2018-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatologic Disease

Keywords

Atopic Dermatitis, serotonin

Brief summary

Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease of unknown aetiology. Global prevalence rates range from 1%-20%.AD is often worsened by stress and anxiety.Plasma levels of 5-HT were found to be positively correlated with the disease severity.

Detailed description

Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease of unknown aetiology. The condition typically starts in infancy with changing presentations over the years. Incessant pruritus is the main symptom. Main findings include: xerosis, eczematous lesions, Ig E reactivity, relapsing course and personal or family history of other atopic diatheses .Global prevalence rates range from 1%-20%. AD is often worsened by stress and anxiety. Moreover, a mutual relationship between the neuroendocrine system and the immune system; including the skin has been suggested. Different mediators are responsible for this relation. Serotonin is considered as one of the most important responsible mediators (5-hydroxy-tryptamine; 5-HT) . Patients with AD have been reported to have high serum levels of 5-HT. Moreover, plasma levels of 5-HT were found to be positively correlated with the disease severity. However and to the best of the investigators' knowledge, no studies have addressed this point in Egypt. Treatment of AD includes: Elimination of triggers, emollients, topical therapies, and systemic modalities including SSRIs (Selective Serotonin Reuptake Inhibitors) and TCAs (Tricyclic Antidepressants) in certain cases. SSRIs block the reuptake of serotonin, thus increase the concentration of serotonin within synaptic clefts. The mechanism of action in relation to pruritus is not understood, but SSRIs have been used to treat atopic dermatitis associated pruritus

Interventions

DIAGNOSTIC_TESTSerum serotonin level

blood sample will be obtained to evaluate serum level of serotonin

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All patients with the clinical diagnosis of AD. * Age more than 2

Exclusion criteria

* Age less than 2 years. * Any concomitant systemic or dermatological disease. * Patients on any topical or systemic treatment during the past one month. * Uncooperative patients. * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
SCORADone monthScoring Atopic Dermatitis SCORAD is a clinical tool for assessing the severity of AD as objectively as possible. It includes: A: Spread B: Intensity C: Subjective symptoms

Secondary

MeasureTime frameDescription
Beck's depression score (Arabic version)one monthits a psychiatric 13 items questionnaire to determine the severity of depression

Contacts

Primary ContactEman R Hofny, Professor
e_riad@yahoo.com01005298992
Backup ContactAyman M Mahran, Lecturer
aymanderma@yahoo.com01009948311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026